A BILL 
To amend title XVIII of the Social Security Act to require 
the Secretary of Health and Human Services to add 
a new set of measures to the 5-star rating system under 
the Medicare Advantage program in order to encourage 
increased access to biosimilar biological products. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Star Rating for 
4
Biosimilars Act’’. 
5
02:47 Jun 08, 2021
H2855
2 
•HR 2855 IH
SEC. 2. ADDITION OF NEW MEASURES BASED ON ACCESS 
1
TO BIOSIMILAR BIOLOGICAL PRODUCTS TO 
2
THE 5-STAR RATING SYSTEM UNDER MEDI-
3
CARE ADVANTAGE. 
4
(a) IN GENERAL.—Section 1853(o)(4) of the Social 
5
Security Act (42 U.S.C. 1395w–23(o)(4)) is amended by 
6
adding at the end the following new subparagraph: 
7
‘‘(E) ADDITION OF NEW MEASURES BASED 
8
ON ACCESS TO BIOSIMILAR BIOLOGICAL PROD-
9
UCTS.— 
10
‘‘(i) IN
GENERAL.—For 2022 and 
11
subsequent years, the Secretary shall add a 
12
new set of measures to the 5-star rating 
13
system based on access to biosimilar bio-
14
logical products covered under part B and, 
15
in the case of MA–PD plans, such prod-
16
ucts that are covered part D drugs. Such 
17
measures shall assess the impact a plan’s 
18
benefit structure may have on enrollees’ 
19
utilization of or ability to access biosimilar 
20
biological products, including in compari-
21
son to the reference biological product, and 
22
shall include measures, as applicable, with 
23
respect to the following: 
24
‘‘(I) 
COVERAGE.—Assessing 
25
whether a biosimilar biological prod-
26
02:47 Jun 08, 2021
H2855
3 
•HR 2855 IH
uct is on the plan formulary in lieu of 
1
or in addition to the reference biologi-
2
cal product. 
3
‘‘(II) 
PREFERENCING.—Assess-
4
ing tier placement or cost sharing for 
5
a biosimilar biological product relative 
6
to the reference biological product. 
7
‘‘(III) 
UTILIZATION
MANAGE-
8
MENT TOOLS.—Assessing whether and 
9
how utilization management tools are 
10
used with respect to a biosimilar bio-
11
logical product relative to the ref-
12
erence biological product. 
13
‘‘(IV) 
UTILIZATION.—Assessing 
14
the percentage of enrollees prescribed 
15
the biosimilar biological product when 
16
the reference biological product is also 
17
available. 
18
‘‘(ii) DEFINITIONS.—In this subpara-
19
graph, the terms ‘biosimilar biological 
20
product’ and ‘reference biological product’ 
21
have the meaning given those terms in sec-
22
tion 1847A(c)(6). 
23
‘‘(iii) PROTECTING
PATIENT
INTER-
24
ESTS.—In developing such measures, the 
25
02:47 Jun 08, 2021
H2855
4 
•HR 2855 IH
Secretary shall ensure that each measure 
1
developed to address coverage, preferenc-
2
ing, or utilization management is con-
3
structed such that patients retain equal ac-
4
cess to appropriate therapeutic options 
5
without undue administrative burden.’’. 
6
(b) CLARIFICATION REGARDING APPLICATION
TO 
7
PRESCRIPTION DRUG PLANS.—To the extent the Sec-
8
retary of Health and Human Services applies the 5-star 
9
rating system under section 1853(o)(4) of the Social Secu-
10
rity Act (42 U.S.C. 1395w–23(o)(4)), or a similar system, 
11
to prescription drug plans under part D of title XVIII of 
12
such Act, the provisions of subparagraph (E) of such sec-
13
tion, as added by subsection (a) of this section, shall apply 
14
under the system with respect to such plans in the same 
15
manner as such provisions apply to the 5-star rating sys-
16
tem under such section 1853(o)(4). 
17
Æ 
02:47 Jun 08, 2021
H2855
